Practical management of glucagon-like peptide-1 receptor agonists in gastroenterology: a position paper by the Italian Society of Gastroenterology (SIGE) - PubMed
5 hours ago
- #gastroenterology
- #GLP-1 receptor agonists
- #diabetes management
- GLP-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes and obesity, with implications for gastroenterology.
- The position paper by SIGE provides evidence-based recommendations for managing GLP-1RAs, emphasizing their benefit-risk profile.
- GLP-1RAs are safe for patients with metabolic dysfunction-associated steatotic liver disease and may reduce hepatic decompensation in cirrhotic patients.
- No increased risk of esophageal, gastric, colorectal, or pancreatic cancer is associated with GLP-1RAs; they may reduce hepatocellular carcinoma risk.
- Routine discontinuation of GLP-1RAs before upper gastrointestinal endoscopy is unnecessary.
- GLP-1RAs are linked to mild, transient gastrointestinal adverse events and cholelithiasis but not severe complications or acute pancreatitis.